A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study)

“…4 While CIT is increasingly restricted in CLL, recent findings have revealed that front-line fixed-duration combinations with fludarabine-based CIT and BTKi could lead to remarkable response rates and PFS. [7][8][9] The potential impact of genetic abnormalities regarding IGHV status may be examined in this context, should such combinations be developed in the future. Unlike CIT, durable remissions are seen with 1L venetoclax combination and BTKi, regardless of IGHV status, del(11q) or mutations in ATM, SF3B1, BIRC3 and NOTCH1.…”

“…Recently, the fixed-duration combination of BTKi and CIT for 1L treatment of CLL patients was shown to achieve a high rate of undetectable minimal residual disease (MRD) and sustained long-term remission even after discontinuing BTKi. [7][8][9] The aim of this study was to evaluate, in prospective trials using 1L CIT, the frequencies of gene mutations, their association with IGHV status and cytogenetic abnormalities and their impact on outcome. To address these questions, we undertook an integrative study including karyotype, fluorescence in situ hybridization (FISH), IGHV status and targeted next-generation sequencing (NGS) in two French prospective clinical trials using 1L CIT.…”